Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting

NCT01755416 on ClinicalTrials.gov · last registry update 2018-08-21

A small phase 2 — 18 participants, against a typical 110. The sponsor logged completion for January 2015. Primary outcome, as filed: Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Albert Einstein College of Medicine
Sponsor type: Other
Enrollment: 18
Started: 2013-01
Primary completion: 2015-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone

Conditions studied

Type 1 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.